arrow
E

Emanuele Cencini

University of Siena
H指数:22
被引数:1,942

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The use of Bruton-tyrosine kinase inhibitors in non-IgM lymphoplasmacytic lymphoma: a retrospective Italian study

布鲁顿酪氨酸激酶抑制剂在非IgM淋巴浆细胞样淋巴瘤中的应用:一项意大利回顾性研究

2026-09-250
PRE
Survival after first relapse in marginal zone lymphomas: Prospective data from the international observational NF10 study

边缘区淋巴瘤首次复发后的生存情况:国际观察性NF10研究的前瞻性数据

2026-09-060
OAAI
Role of direct-acting antivirals in people with HIV-associated non-Hodgkin lymphoma and concomitant HCV infection: A study on behalf of the Fondazione Italiana Linfomi

直接抗病毒药物在合并HCV感染的HIV相关非霍奇金淋巴瘤患者中的作用:意大利淋巴瘤基金会研究

2026-09-060
PRE
Renal dysfunction in symptomatic Waldenström macroglobulinaemia: A nationwide Italian multicentre study

症状性华氏巨球蛋白血症的肾功能不全:一项意大利全国多中心研究

2026-03-080
OAAI
Ibrutinib or non-BTK inhibitor therapy in relapsed Waldenström Macroglobulinaemia? A real-life multicentre Italian study.

伊布替尼或非BTK抑制剂疗法在复发华氏巨球蛋白血症中的应用?一项意大利多中心真实世界研究。

2026-02-160
OAAI
Total Metabolic Tumor Volume Is a Strong Independent Prognostic Factor in Follicular Lymphomas: Results From a Sub-Study of the FOLL12 Trial

总代谢肿瘤体积是滤泡性淋巴瘤的一个强独立预后因素:FOLL12试验子研究的结果

2025-05-140
OA
Comparative Effectiveness of R-miniCOMP Versus R-miniCHOP in Older Non-Fit Patients With Diffuse Large B-Cell Lymphoma: Insights From a Fondazione Italiana Linfomi Cohort Study

R-miniCOMP与R-miniCHOP在老年非适合型弥漫大B细胞淋巴瘤患者中的比较疗效:来自意大利淋巴瘤基金会队列研究的见解

2025-05-130
PRE
First-line treatment of Waldenstrom's macroglobulinemia in Italy: A multicenter real-life study on 547 patients to evaluate the long-term efficacy and tolerability of different chemoimmunotherapy strategies
2024-11-190
OAAI
Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatment
2024-06-013
OAAI
A Fondazione Italiana Linfomi cohort study of R-COMP vs R-CHOP in older patients with diffuse large B-cell lymphoma
2023-08-015
OAAI
Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL
2023-07-278
OAAI
Ibrutinib in relapsed/refractory patients with Waldenstrom macroglobulinemia: a real-life, retrospective study on behalf of the RTL (regional Tuscan lymphoma network)
2023-02-031
PRE
Diffuse large B-cell lymphoma in octogenarians aged 85 and older can benefit from treatment with curative intent: a report on 129 patients prospectively registered in the Elderly Project of the Fondazione Italiana Linfomi (FIL)
2022-11-1713
OAAI
The elderly prognostic index predicts early mortality in older patients with diffuse large B-cell lymphoma. An ad hoc analysis of the elderly project by the Fondazione Italiana Linfomi
2022-10-077
PRE
An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma
2022-03-2921
OAAI
Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study)
2022-02-019
OAAI